About Ovantic Life Sciences
Pharmaceutical Manufacturing, Regulatory Discipline, and Targeted Innovation
Ovantic Life Sciences is a U.S.-based pharmaceutical manufacturing and life sciences organization focused on the development, production, and supply of regulated pharmaceutical products, active pharmaceutical ingredients (APIs), and specialty therapies. Our operations are built on cGMP manufacturing standards, regulatory compliance, and disciplined execution across the product lifecycle.
In parallel with our manufacturing platform, Ovantic advances targeted research and development programs addressing rare and underserved diseases, with a long-term commitment to improving patient access, treatment continuity, and therapeutic outcomes.
Who We Are
Ovantic Life Sciences operates as a vertically integrated pharmaceutical organization supporting regulated markets through manufacturing, quality systems, and technical expertise. We serve licensed partners, healthcare institutions, and research collaborators seeking a reliable, compliant, and scalable life sciences partner.
Our work spans pharmaceutical manufacturing, API sourcing and oversight, selective private label programs, and orphan drug development—each governed by structured quality systems and regulatory alignment.
Our Mission
Executive Management
Ovantic Life Sciences is led by an experienced team of executives, scientific leaders, and regulatory advisors with deep expertise across pharmaceutical manufacturing, compliance, clinical oversight, and global market access.
Our leadership structure is designed to ensure clear accountability across manufacturing and quality operations, strong regulatory governance and inspection readiness, and disciplined decision-making throughout development and commercialization.
Terrance Sky
Chief Executive Officer & President
Terrance Sky serves as Chief Executive Officer and President of Ovantic Life Sciences, where he oversees corporate strategy, pharmaceutical manufacturing operations, regulatory alignment, and business development. He leads the company with a focus on quality-driven manufacturing, regulatory compliance, and disciplined growth across regulated markets.
Prior to leading Ovantic Life Sciences, Mr. Sky held leadership and advisory roles supporting pharmaceutical and healthcare organizations in navigating FDA regulatory frameworks, strengthening quality systems, optimizing manufacturing operations, and advancing compliant product commercialization. His experience spans pharmaceutical manufacturing, regulatory affairs, and healthcare consulting.
Mr. Sky’s leadership is grounded in operational discipline, scientific integrity, and long-term value creation. Under his direction, Ovantic Life Sciences continues to expand its manufacturing capabilities and strategic partnerships, supporting the development and supply of regulated pharmaceutical products with a consistent focus on quality and compliance.
Robert Sharpneck
Chief Operating Officer, Ovantic Life Sciences
Robert Sharpneck serves as Chief Operating Officer of Ovantic Life Sciences, overseeing the company’s global operations, regulatory strategy, and execution. With extensive experience working with the U.S. Food and Drug Administration (FDA) and advising life science companies, Robert ensures that Ovantic’s research and manufacturing processes meet the highest standards of compliance, efficiency, and scalability.
He brings a strong background in regulatory consulting, operational management, and quality systems, guiding teams in translating scientific innovation into commercially viable, compliant products. At Ovantic, Robert leads cross-functional alignment between R&D, manufacturing, and quality divisions—driving operational excellence and positioning the company for sustainable growth in the pharmaceutical and life sciences markets.
Katy Pena
Vice President, Business Development — U.S. & Caribbean
Katy Pena serves as Vice President of Business Development for the U.S. and Caribbean markets at Ovantic Life Sciences, bringing extensive experience in global pharmaceutical partnerships, licensing, and commercial growth strategy. With a proven background in identifying market opportunities and developing high-value collaborations, she drives Ovantic’s expansion across key territories.
Katy has worked with leading pharmaceutical and life science organizations throughout her career, negotiating strategic alliances and guiding successful product launches. At Ovantic, she focuses on building strong partnerships, enhancing market reach, and accelerating access to innovative healthcare solutions throughout the U.S. and Caribbean.
Mohammed Al-Sultan
Vice President, Business Development – GCC Region
Mohammed Al-Sultan serves as Vice President of Business Development for Ovantic Life Sciences in the Gulf Cooperation Council (GCC) region. He leads the company’s strategic growth and partnership initiatives across Saudi Arabia, the UAE, Kuwait, Qatar, Oman, and Bahrain. With extensive experience in regional healthcare markets, Mohammed drives commercial expansion, regulatory alignment, and institutional collaboration to strengthen Ovantic’s presence and deliver innovative pharmaceutical solutions throughout the GCC.
Kamel Moustafa
Vice President, Business Development – MENA Region
Kamel Moustafa serves as Vice President of Business Development for Ovantic Life Sciences in the Middle East and North Africa (MENA) region. He is responsible for leading the company’s strategic growth initiatives, market expansion, and institutional partnerships across a diverse network of healthcare systems, government agencies, and pharmaceutical distributors.
With extensive experience in international business development and the life-sciences sector, Kamel brings deep regional insight and a results-driven approach to advancing Ovantic’s mission of improving access to high-quality pharmaceutical products throughout the MENA region. His leadership focuses on building sustainable partnerships, strengthening regulatory alignment, and driving commercial excellence in emerging markets.
Ren Kuili
Vice President, Product Acquisition (Asia)
Ren Kuili serves as Vice President of Product Acquisition (Asia) for Ovantic Life Sciences, where he leads the company’s efforts to identify, evaluate, and secure high-value pharmaceutical and life science products across the Asian region. With extensive experience in international business development and pharmaceutical sourcing, Ren drives Ovantic’s strategic growth through partnerships with leading manufacturers, research institutions, and distributors.
His background includes leadership roles in global product acquisition, licensing, and regulatory coordination, giving him deep insight into Asian market dynamics and compliance standards. Ren’s expertise ensures that Ovantic continues to expand its global portfolio with innovative, high-quality products that meet regional and international standards.
Ralph Navarro
Advisor, Technical & Compliance
Ralph serves as Advisor of Technical and Compliance for Ovantic Life Sciences, bringing over 25 years of experience in the biotechnology and pharmaceutical industries. He specializes in regulatory compliance, quality systems, and operational remediation, with extensive experience working directly with global health authorities, including the FDA.
Throughout his career, Ralph has successfully led corrective and preventive action (CAPA) initiatives, site-wide remediation programs, and compliance responses to FDA 483s, Warning Letters, and Consent Decrees. His deep technical knowledge and regulatory insight help ensure that Ovantic maintains the highest standards of quality, safety, and operational excellence across all its facilities and product lines.
William E. Burmeister
Chief Scientific Training Officer
William E. Burmeister is a pharmaceutical research professional with decades of experience in pharmacology and toxicology. He trained in physiology at Eastern Michigan University and conducted cardiovascular pharmacology research at the University of Michigan Medical School before joining Parke-Davis (Warner-Lambert), where he spent more than two decades in scientific and experimental toxicology roles.
Following his tenure with Pfizer, he served as Director of Practicum Education at the University of Toledo College of Pharmacy, where he expanded a nationally recognized internship program. Mr. Burmeister has authored multiple peer-reviewed publications and abstracts.
Mr. Burmeister advises Ovantic Life Sciences on pharmaceutical development and scientific strategy.
Michael Hines
Chief Financial Officer
Michael Hines serves as Chief Financial Officer for Ovantic Life Sciences, bringing more than 30 years of experience in finance, accounting, and strategic planning. He oversees all financial operations of the company, including budgeting, forecasting, and financial reporting, while guiding long-term fiscal strategy and growth initiatives.
Throughout his career, Michael has worked with leading Fortune 500 companies across healthcare and industrial sectors, where he developed a strong reputation for financial leadership, operational efficiency, and business insight. At Ovantic, he ensures sound financial governance and sustainable growth to support the company’s mission of advancing innovation in life sciences.
Terrance Sky
Terrance Sky is the Chief Executive Officer and President of Ovantic Life Sciences, where he leads the company’s strategic growth, innovation, and global operations. With extensive experience in pharmaceutical manufacturing, regulatory compliance, and healthcare consulting, Terrance oversees all facets of Ovantic’s development—from research and formulation to commercialization and strategic partnerships.
Before founding Ovantic Life Sciences, Terrance served as a trusted consultant to multiple life science and healthcare organizations, helping them navigate FDA regulations, optimize production systems, and bring compliant, high-quality products to market. His leadership philosophy centers on operational excellence, scientific integrity, and advancing accessible healthcare solutions worldwide.
Under his direction, Ovantic Life Sciences continues to expand its footprint as a trusted innovator in pharmaceuticals and wellness, dedicated to improving patient outcomes through quality, research, and technology.
Robert Sharpneck
Katy Pena
Mohammed Al-Sultan
Kamel Moustafa
Ren Kuili
Ralph Navarro
Bill Burmeister
Dr. Chris Alvarado, D.O.
Michael Hines
Operations, Quality & Compliance Leadership
Medical & Scientific Leadership
Regulatory & Quality Commitment
Compliance & Certifications
Quality and product safety are our top priorities. Ovantic operates under current Good Manufacturing Practice (cGMP) for drug products as outlined in 21 CFR 210 and 211, and applies a lifecycle approach to quality consistent with ICH Q10.
For medical-surgical products, we follow ISO 13485 principles where appropriate. We partner only with manufacturers that maintain FDA registration, strong audit histories, and clear change-control systems.
Our distribution practices align with DSCSA traceability and Good Distribution Practice (GDP) standards, ensuring transparent labeling and full lot-to-label documentation.
Commitment to Rare Disease Innovation
Our Approach
Contact & Inquiries
Commitment to Rare Disease Innovation
Ovantic supports rare disease communities by forming targeted partnerships for hard-to-find therapies and reformulated treatments. We work to improve usability, simplify instructions, and reduce stockouts through strategic distribution planning.
Our goal is to bring clarity, reliability, and compassion to conditions that are often overlooked, helping patients access the care they deserve.